AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04648917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Caffeic acid
Description: 40 patients will receive coffeic acid treatment: 100-200mg, tid, po, 2 weeks treated then 1 week black interval(weight >50kg, 200mg per time, weight \< or =50kg, 100mg per time)
Study NCT01110226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be given to all patients at a dose of 75 mg/m2 on day 1 of every 21 day cycle over 30 to 90 minutes through an intravenous infusion immediately after the first dose of KML-001
Study NCT00555282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: central venous catheter
Description: coated central venous catheter
Study NCT00555282 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: central venous catheter
Description: standard central venous catheter
Study NCT00602771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tipifarnib
Description: Given orally
Study NCT04340921 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID-19 exposure
Description: Observation only
Study NCT00602771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given orally
Study NCT03991182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMAGs trained on ECD curriculum
Description: 50 volunteers (primarily SMAGs- Safe Motherhood Action Group members) associated with the health facility will be trained using a training -of-trainers approach on the e ECD (early childhood development) curriculum
Study NCT03991182 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Head women trained on ECD curriculum
Description: Each of the 50 trained SMAGs will train 10 head women on the ECD curriculum
Study NCT03991182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Head women led parent groups
Description: Every two weeks 500 trained head women lead parent group meetings on childhood development and nutrition to caregiver-child dyads
Study NCT03991182 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care of children 0-5 months
Description: The traditional care and education of caregivers/parents for children 0-5 months
Study NCT00750178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat (MK0683 )
Description: Panel A: vorinostat 400 mg capsules once daily on Days 1, 5, 7-28~Total treatment period is 28 days
Study NCT00807014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duac Gel
Description: Duac® Gel will be applied to the face once daily at night, for 12 weeks.
Study NCT00807014 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Differin gel
Description: Differin Gel will be applied to the face once daily at night, for 12 weeks.
Study NCT03418064 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fanfilcon A toric lens
Description: Contact lens
Study NCT03418064 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lotrafilcon B toric lens
Description: Contact lens
Study NCT02052141 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CINRYZE 500
Description: 500 Units of CINRYZE administered by IV injection
Study NCT02052141 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CINRYZE 1000
Description: 1000 Units of CINRYZE administered by IV injection
Study NCT00594087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eszopiclone
Description: eszopiclone 2mg or 3mg at bedtime
Study NCT00594087 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 mg or 3 mg at bedtime
Study NCT02901340 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: one to two liters of water daily
Study NCT01961089 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Galilei Lens Professional
Description: Measurement device
Study NCT01961089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Galilei Lens Professional
Description: Measurement device
Study NCT01961089 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOLMaster
Description: Measurement device
Study NCT01961089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOLMaster
Description: Measurement device
Study NCT01961089 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lenstar
Description: Measurement device
Study NCT01961089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lenstar
Description: Measurement device
Study NCT02314871 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia
Description: see Arm/group description
Study NCT02314871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piritramide
Description: see Arm/group description
Study NCT02314871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: see Arm/group description
Study NCT03447119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living Well with a Disability
Description: Implementation of an adapted health promotion program.
Study NCT00890669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill walking training with additional body load
Description: The training program was divided into three phases (A1-B-A2):~* treadmill training with additional body load (A1),~* control condition (conventional physical therapy group) (B). and~* treadmill training with additional body load again (A2).~Each phase lasted six weeks, totaling 18 weeks. Both evaluations and training were performed during on-phase of the medication cycle.
Study NCT02565446 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resolution Elastography (MRE)
Description: Magnetic Resolution Elastography (MRE): Three-dimensional magnetic resonance elastography (3DMRE), Waves at frequencies of 30 Hz, 40 Hz, and 60 Hz.
Study NCT00845507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: The dosage of study medication will be 5 mcg injection of exenatide twice daily for 28 days. On day 28 the dosage may be increased, as tolerated, to 10 mcg twice daily.
Study NCT00845507 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: Sterile solution in equivalent doses as Exenatide
Study NCT00953225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: 4,000 IU daily for one year
Study NCT01845831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine
Description: Patients with blood glucose between 140-200 mg/dL during hospitalization will receive 0.2 units per kg weight per day.~Patients with blood glucose between 201-400 mg/dL during hospitalization will receive 0.25 units per kg weight per day.
Study NCT00953225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo daily for one year
Description: Placebo
Study NCT01590667 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Litramine
Description: 2 tablets 3 times daily (oral consumption, 30 minutes after meal)
Study NCT01590667 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets 3 times daily (oral consumption, 30 minutes after meal)
Study NCT00430885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octagam (IVIG)
Description: Intravenous immunoglobulin 0.4 g/kg given as infusion
Study NCT00430885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Octagam (IVIG)
Description: Intravenous immunoglobulin 0.4 g/kg given as infusion
Study NCT03612947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine +magnesium sulphate
Description: Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine) plus 150 mg of MgSo4
Study NCT03612947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine only
Description: Ultrasound guided subcostal TAP block will performed on both sides using 20 ml volume (0.25 bupivacaine).
Study NCT02733926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adding of vegetation into the backyards of kindergarten
Description: Living plants are transferred into the backyards of kindergartens. This is assumed to affect the measured variables of children.
Study NCT00369317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: Given IM
Study NCT00369317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV
Study NCT00369317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV or IT
Study NCT00369317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine
Description: Given orally
Study NCT00369317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT00369317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03277482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is given by intravenous infusion every 4 weeks for a maximum of 13 doses over 52 weeks. One cycle is defined as every 4 weeks. Each infusion will take approximately 1 hour.
Study NCT03277482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab is given by intravenous infusion every 4 weeks for a maximum of 4 doses over 16 weeks. One cycle is defined as every 4 weeks. If receiving both durvalumab and tremelimumab for the first 4 cycles, they will be given on the same day. Each infusion will take approximately 1 hour
Study NCT03277482 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation treatment will begin on the same day as the first immunotherapy infusion or on the following day. The radiation treatment course is either 1 day or 5 days.
Study NCT03420664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthosis VACOped
Description: Orthosis for lower limb immobilisation
Study NCT03420664 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Below knee cast
Description: Below knee cast for lower limb immobilisation
Study NCT01297465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gonal-f®
Description: Gonal-f® (follitropin alfa) 300 International Unit (IU) will be administered subcutaneously once daily from stimulation day 1 (S1) to stimulation day 5 (S5).
Study NCT01297465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pergoveris®
Description: Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously starting from S6 until recombinant human chorionic gonadotropin (r-hCG) administration day (at least 1 follicles >= 18 mm). The dose of Pergoveris® was adjusted based upon the participant's ovarian response and according to the site's standard practice.
Study NCT01297465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pergoveris®
Description: Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously once daily from S1 until r-hCG administration day (at least 1 follicles >= 18 mm). The dose of Pergoveris® was adjusted starting from S6 based upon the participant's ovarian response and according to the site's standard practice.
Study NCT01297465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human chorionic gonadotropin (r-hCG)
Description: 250 microgram of r-hCG will be administered once subcutaneously on r-hCG day (at least 1 follicles >= 18 mm).
Study NCT01297465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human chorionic gonadotropin (r-hCG)
Description: 250 microgram of r-hCG will be administered once subcutaneously on r-hCG day (at least 1 follicles >= 18 mm).
Study NCT04412265 — intervention group
Intervention type: OTHER
Intervention: Relation between frailty and clinical outcomes in elderly patients with COVID-19.
Description: To evaluate whether a tool built to measure frailty in elderly patients hospitalized in COVID + hospital departments are more accurate in predicting clinical outcomes compared to a clinical evaluation based on age and comorbidity. If the assessment of fragility were actually more accurate, the tool developed could be implemented in hospitals to support the clinician 's choices regarding the roof of care and actions to be taken undertake to prevent deterioration.
Study NCT00920517 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rDEN2/4delta30(ME) vaccine
Description: 10\^3 PFU dose
Study NCT00920517 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo for rDEN2/4delta30(ME) vaccine
Study NCT03891966 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rigid Splint
Description: 50 patients undergoing operative fixation of isolated bothbone forearm, radial head, olecranon, distal humerus, or humeral shaft fractures will either receive a splint.
Study NCT03891966 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Soft Dressing
Description: 50 patients undergoing operative fixation of isolated both bone forearm, radial head, olecranon, distal humerus, or humeral shaft fractures will either receive a soft dressing post-operatively.
Study NCT01239875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dendritic cell vaccine therapy
Description: Given intratumorally
Study NCT01239875 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: Undergo cryoablation
Study NCT01239875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pneumococcal polyvalent vaccine
Description: Given intramuscularly
Study NCT01239875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01239875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Correlative studies
Study NCT01239875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT01239875 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cell-tumor fusion vaccine
Description: Given intradermally
Study NCT02161822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: simvastatin 80mg qd for 5weeks
Study NCT01845831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine 50%
Description: Glargine will be prescribed at 50% of daily hospital dose.
Study NCT01845831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine 80%
Description: Glargine will be prescribed at 80% of daily hospital dose.
Study NCT02817308 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: samples of blood, saliva and urine
Description: Spot samples of Blood, urine and saliva
Study NCT02817308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: samples of blood, saliva and urine
Description: Spot samples of Blood, urine and saliva
Study NCT01048177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bladder instillation with heparin/ lidocaine
Description: 9 bladder instillations in 6 weeks
Study NCT00760097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct stimulation
Description: sessions of 20 minutes each
Study NCT01848691 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of carbon monoxide level in exhaled breath
Description: Measurement of end-tidal carbon monoxide concentration
Study NCT01848691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement of carbon monoxide level in exhaled breath
Description: Measurement of end-tidal carbon monoxide concentration
Study NCT00067665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Description: All patients participating in the trial require evaluation of dry-weight at each dialysis visit for evaluation. An initial weight loss of 0.1kg/10 kg body-weight will be prescribed per dialysis. If ultrafiltration is not tolerated based on muscle cramps, need for excessive saline or symptomatic hypotension, the intensity of ultrafiltration will be reduced by 50%. If ultrafiltration is still not tolerated, the weight loss will be further reduced by 50%. If the patient cannot tolerate at least 0.2 kg incremental weight loss per dialysis, the patient will be said to be at goal dry-weight. Thus, by this protocol, all patients must experience symptoms of volume depletion to be at dry weight.
Study NCT02195583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (1426 ppm)
Description: Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base
Study NCT04036201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: peribulbar block
Study NCT02195583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (1150 ppm)
Description: Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base
Study NCT02195583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (250 ppm)
Description: Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base
Study NCT02195583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (1426 ppm) + zinc base A
Description: Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base
Study NCT02195583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (1426 ppm) + zinc base B
Description: Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base
Study NCT02195583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride (0 ppm)
Description: Non-zinc, 0ppm fluoride in a silica gel base
Study NCT00514111 — intervention group
Intervention type: DRUG
Intervention: pegylated-interferon, conventional-interferon, ribavirin
Description: Genotype 1: pegylated-interferon 2a or 2b plus ribavirin for 48 weeks. Genotype 3: conventional-interferon 2a or 2b plus ribavirin for 24 weeks.
Study NCT02285192 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-Fluorodeoxyglucose (18F-FDG)
Study NCT02285192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT imaging
Study NCT02285192 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/MRI imaging
Study NCT03822143 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Use of ultrasound device to diagnosis anemia in a fetus
Study NCT02924259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The GRID foam roll
Description: Commercial rigid foam roll with an outer foam covering
Study NCT02266147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101
Study NCT02266147 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Study NCT02748252 — intervention group
Intervention type: OTHER
Intervention: stroke center referral
Study NCT02211937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 44847 solution, low dose
Study NCT02211937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 44847 suspension, high dose
Study NCT02211937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44847 tablet, low dose
Study NCT02211937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44847 tablet, high dose
Study NCT02211937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high fat breakfast
Study NCT02788812 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open modified Lichtenstein repair
Description: Open Lichtenstein Hernioplasty
Study NCT04388215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CKD-828
Description: orally, 1 tablet once a day for 8 weeks
Study NCT04388215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-828
Description: orally, 1 tablet once a day for 8 weeks
Study NCT04388215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CKD-828(placebo)
Description: orally, 1 tablet once a day for 8 weeks
Study NCT04388215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D326
Description: orally, 1 tablet once a day for 8 weeks
Study NCT04388215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D326
Description: orally, 1 tablet once a day for 8 weeks
Study NCT04388215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D326(placebo)
Description: orally, 1 tablet once a day for 8 weeks
Study NCT04388215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D337
Description: orally, 1 tablet once a day for 8 weeks
Study NCT04388215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D337
Description: orally, 1 tablet once a day for 8 weeks
Study NCT04388215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D337(placebo)
Description: orally, 1 tablet once a day for 8 weeks
Study NCT04388215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D013
Description: orally, 1 tablet once a day for 8 weeks
Study NCT04388215 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D013(placebo)
Description: orally, 1 tablet once a day for 8 weeks